Sino Biopharmaceutical's (HKG:1177) TQB2101 anti-tumor obtained Chinese implied approval for clinical trials, according to a Thursday filing with the Hong Kong bourse.
The drug showed anti-tumor activity in receptor tyrosine kinase-like orphan receptor-1-positive tumor models during preclinical studies, the filing said.
ROR-1 is seen in lung, pancreatic, breast, colorectal, and ovarian cancers, the filing said.
Separately, China's medical products administrator accepted Sino Biopharm's clinical trial application for its TQB6411 anti-lung cancer drugs.
The drug targets the epidermal growth factor receptor and cell mesenchymal epithelial transition present as lung cancer driver genes, according to a separate Thursday filing.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。